Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications

Abstract

Bortezomib (BTZ) is a first-in-class reversible and selective proteasome inhibitor. It inhibits the ubiquitin proteasome pathway that leads to the degradation of many intracellular proteins. Initially, BTZ was FDA approved for the treatment of refractory or relapsed multiple myeloma (MM) in 2003. Later, its usage was approved for patients with previously untreated MM. In 2006, BTZ was approved for the treatment of relapsed or refractory Mantle Cell Lymphoma (MCL) and, in 2014, for previously untreated MCL. BTZ has been extensively studied either alone or in combination with other drugs for the treatment of different liquid tumors especially in MM. However, limited data evaluated the efficacy and safety of using BTZ in patients with solid tumors. In this review, we will discuss the advanced and novel mechanisms of action of BTZ documented in MM, solid tumors and liquid tumors. Moreover, we will shed the light on the newly discovered pharmacological effects of BTZ in other prevalent diseases.

Anti-COVID Drugs (MMV COVID Box) as Leishmanicidal Agents: Unveiling New Therapeutic Horizons

“…Furthermore, considering the broad-spectrum activity of the compounds evaluated, they are likely to show significant efficacy against other pathogenic microorganisms. For instance, bortezomib corresponds to a pioneering proteasome inhibitor approved in 2003 by the FDA for the treatment of refractory or relapsed multiple myeloma [ 17 ]. It selectively and reversibly disrupts the ubiquitin-proteasome pathway, whose inhibition in the Leishmania genus is known to block parasite proliferation and differentiation, thereby altering its virulence factor [ 18 ].…”

NF-κB in biology and targeted therapy: new insights and translational implications

“…Bortezomib is a first-in-class selective and reversible proteasome inhibitor, which binds to and inhibits the activity of the 26 S proteasome, a cellular complex responsible for degrading and recycling proteins. 546 , 547 By blocking the proteasome’s function, bortezomib was initially thought to inhibit IκB degradation, which is necessary for NF-κB activation. However, it has been later confirmed that bortezomib can also induce activation of canonical NF-κB signaling in multiple myeloma in vitro.…”